

RHEUMATOID ARTHRITIS


Internal Medicine CME Update

Blair Solow, MD, MSc


2021

OUTLINE

- Cases in the differential of Rheumatoid Arthritis
- RA Pathogenesis
- Therapy in RA
- Concluding Remarks



ARTHRITIS ON THE RISE




CDC
Vitalsigns[™]
www.cdc.gov/vitalsigns/arthritis

SOURCE: National Health Interview Survey, 2013-2015.




The United States population on **March 29, 2021** was: **330,169,526**

Select a Date



PROPORTIONS



Arthritis by Numbers, Arthritis Foundation 2020
CDC.gov/arthritis
Singh et al., Rheum (Oxf) 2019
Crowson, et al., Semin Arth Rheum 2017
Ogdie, et al., Rheum Disc Clin N Amer 2015

CASE 1

- A 59-year-old male presents to your office with worsening pain in his hands, wrists, and knees over the past 9 months. He feels **stiff** in the morning for **15 minutes** and notes **occasional swelling** in his knees after prolonged walking or standing.
- He works as a bus mechanic and does not smoke or drink. When working he reports more pain in hands and knees at the **end of the day**.
- His mother and brother have “arthritis”.



CASE 1

- Labs:
 - Normal CBC
 - Normal creatinine
 - Liver mild elevation AST: 45 ALT: 52
 - ESR 20, CRP normal
 - **Rheumatoid Factor 66** (nl<14 IU/ml), **anti-CCP 28** (nl<20 U/ml)
 - **Hepatitis C positive**, Hepatitis B negative
- Xray of hands and knees shows mild degenerative changes




CASE 1: HEPATITIS C - ASSOCIATED ARTHROPATHY

- Prevalence of Hepatitis C: ~1.7 %
- Prevalence of HepC associated arthropathy: 2-20 %
- RF in Hepatitis C: 10-70%
- Anti-CCP in Hepatitis C: 0-20% (low levels)

Hofmeister, MG, et al. Hepatology March 2019
Zengin, O, et al. Adv Clin Exp Med Sept 2017
Lienesch D, et al. J Rheum 2005
Clifford, BD, et al. Hepatology 1995

ANTIBODIES: RHEUMATOID FACTOR

Normal	Individuals, especially with age
Arthritis	Rheumatoid arthritis (85%), Sjögren's, Lupus
Viral Infections	Hepatitis C, mononucleosis, HIV
Bacterial Infections	Endocarditis, TB, leprosy, syphilis
Parasites	Trypanosomiasis, malaria
Other	Sarcoidosis, pulmonary fibrosis, liver disease



CASE 2

- A 75-year-old woman presents to your office with worsening joint pain for the past 1 year.
- She wakes with **10 minutes of stiffness** diffusely and reports **swelling** in her fingers. She reports pain in her hands, wrists, shoulders, knees and feet. She cannot open bottled water anymore and keeps dropping her coffee cup.
- She works part-time in accounting and exercises regularly.
- She mentions her mother had “deformed hands” and severe arthritis. Her sister was recently diagnosed with arthritis too.
- She smokes 10 cigarettes per day.



Image from ACR Image bank

CASE 2



CASE 2

- Labs:

- Normal CBC
- Normal liver and creatinine
- ESR 15
- CRP normal
- **Rheumatoid Factor 23** (nl<14 IU/ml), **anti-CCP 45** (nl<20 U/ml)

- Xray of hands and knees reveal joint space narrowing, gull-wing, (central) erosive changes



CASE 2: EROSIVE OSTEOARTHRITIS

- Erosive Osteoarthritis (EOA)
- Why it's not RA:
 - No inflammatory symptoms or labs
 - Exam with bony changes, no synovitis
 - Xray erosive changes related to EOA in PIP and DIP





ANTI-CCP AND RISK OF RA

B


ACPA +

ACPA -

developed RA



ANTIBODIES: ACPA



RHEUMATOID ARTHRITIS





Image from ACR Image bank

RHEUMATOID ARTHRITIS

Incidence 3.6%* and Prevalence 1%



Classification

JOINT DISTRIBUTION (0-5)	
1 large joint	0
2-10 large joints	1
1-3 small joints (large joints not counted)	2
4-10 small joints (large joints not counted)	3
>10 joints (at least one small joint)	5
SEROLOGY (0-3)	
Negative RF <u>AND</u> negative ACPA	0
Low positive RF <u>OR</u> low positive ACPA	2
High positive RF <u>OR</u> high positive ACPA	3
SYMPTOM DURATION (0-1)	
<6 weeks	0
≥6 weeks	1
ACUTE PHASE REACTANTS (0-1)	
Normal CRP <u>AND</u> normal ESR	0
Abnormal CRP <u>OR</u> abnormal ESR	1

≥6 = definite RA

ARTHRITIS & RHEUMATISM
 Vol. 62, No. 9, September 2010, pp 2569-2581
 DOI 10.1002/art.27584
 © 2010, American College of Rheumatology

Arthritis & Rheumatism

An Official Journal of the American College of Rheumatology
 www.arthritisrheum.org and www.interscience.wiley.com

2010 Rheumatoid Arthritis Classification Criteria

An American College of Rheumatology/European League Against Rheumatism
 Collaborative Initiative

Daniel Aletaha,¹ Tuhina Neogi,² Alan J. Silman,³ Julia Funovits,¹ David T. Felson,²
 Clifton O. Bingham, III,⁴ Neal S. Birnbaum,⁵ Gerd R. Burmester,⁶ Vivian P. Bykerk,⁷
 Marc D. Cohen,⁸ Bernard Combe,⁹ Karen H. Costenbader,¹⁰ Maxime Dougados,¹¹
 Paul Emery,¹² Gianfranco Ferraccioli,¹³ Johanna M. W. Hazes,¹⁴ Kathryn Hobbs,¹⁵
 Tom W. J. Huizinga,¹⁶ Arthur Kavanaugh,¹⁷ Jonathan Kay,¹⁸ Tore K. Kvien,¹⁹ Timothy Laing,²⁰
 Philip Mease,²¹ Henri A. Ménéard,²² Larry W. Moreland,²³ Raymond L. Naden,²⁴
 Theodore Pincus,²⁵ Josef S. Smolen,¹ Ewa Stanislawska-Biernat,²⁶ Deborah Symmons,²⁷
 Paul P. Tak,²⁸ Katherine S. Upchurch,¹⁸ Jiří Vencovský,²⁹
 Frederick Wolfe,³⁰ and Gillian Hawker³¹

HISTORICAL PERSPECTIVES



*1800 French medical resident Augustin Jacob Landré-Beauvais

Paleopathological evidence controversial, may pre-date Landré-Beauvais by several hundred (?thousand) years






Old World > New World (1492 Columbus sailed the ocean blue)

Entezami, et al., Hand Clin, 2012



Stetka, et al., Medscape 2016

Panush, 2012 <https://hippocratesinst.org/the-sugar-timeline>

PATHOGENESIS




citrullination




Smolen et al., Lancet 2016
Deane et al., Best Pract Res Clin Rheum 2017
Holers, et al., Nature Rev Rheum 2018

PATHOGENESIS




RHEUMATOID ARTHRITIS XRAYS





ARTICULAR MANIFESTATIONS



EXTRA-ARTICULAR FINDINGS



THERAPY



NSAIDS

Generic NSAIDs Available


NSAID Class	Generic Name	NSAID Class	Generic Name
Salicylates	Salsalate	Acetic acids	Diclofenac potassium
Propionic acids	Fenoprofen		Diclofenac sodium
	Flubriprofen		Etodolac
	Ibuprofen	Sulindac	
	Ketoprofen	Oxicams	Piroxicam
	Naproxen	Naphthyl-alkanones	Nabumetone
	Naproxen sodium		
	Oxaprozin		

Brand-only NSAIDs:


NSAID Class	Generic Name / Proprietary Name
Semi-selective COX-2 inhibitor	Meloxicam / Mobic®
Selective COX-2 inhibitor	Celecoxib / Celebrex®

CORTICOSTEROIDS / PREDNISONONE

- Dosing: 5-10 mg per day
- Bone health + Vitamin D



METHOTREXATE



BIOLOGIC AND SMALL MOLECULE THERAPY








Do you have a diagnosis that's more affordable?

BIOLOGIC AND SMALL MOLECULE THERAPY

- Binding anti-TNF α
- Blocking T cell co-stimulation
- B cell depletion
- Targeting IL-6 / IL-6R
- Inhibiting Jak/Stat pathway

TNF inhibitors



OTHER TREATMENT MODALITIES



Deane, et al., Best Pract Res Clin Rheum 2017
Smolen et al., Nat Rev Dis Prim 2018
Coras, et al., Arth & Rheum 2020 (suppl 10)
Hahn, et al., Arth & Rheum 2020 (suppl 10)

IMMUNOSUPPRESSION AND VACCINATION

- Live virus vaccines should be avoided
- Response to the vaccine may be decreased in some immunosuppressed individuals
- Indicated inactivated Vaccines:
 - Influenza
 - Pneumococcal
 - Hepatitis B
 - Shingrex
 - Covid-19

SUMMARY

- RA is a common inflammatory, autoimmune disease affecting joints and other organs
- Genetics and environment play a role in the development of immune dysregulation
- Methotrexate is the anchor drug
- Biologics target specific immune system functions to reduce inflammation
- Smoking cessation, mediterranean-style diet, and healthy lifestyle may mitigate inflammation

THANK YOU



Renoir

Dance at the Moulin de la Galette (1876)
Musee d'Orsay, Paris

